.

Gut and Liver

Indexed in PubMed / PubMed central , Elsevier Bibliographic Databases (Scopus & Embase)
Science Citation Index Expanded (SCIE), Google Scholar / KoreaMed
Articles

Predictive Role of Acute Phase Reactants in the Response to Therapy in Patients with Chronic Hepatitis C Virus Infection

Ayten Oguz*, Ahmet Engin Atay, Adnan Tas, Gulseren Seven, and Mehmet Koruk
*Department of Internal Medicine, Gaziantep University Faculty of Medicine, Gaziantep, Department of Internal Medicine, Dicle University School of Medicine, Diyarbakr, Department of Gastroenterology, Osmaniye Public Hospital, Osmaniye, Department of Gastroenterology, Ankara University Faculty of Medicine, Ankara, and Department of Gastroenterology, Gaziantep University Faculty of Medicine, Gaziantep, Turkey
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
ABSTRACT
Background/Aims: Biochemical parameters and acute-phase proteins (APPs) may provide complementary data in patients with chronic hepatitis C (CHC). We aimed to evaluate the predictive role of APPs in the response to antiviral therapy.
Methods: Forty-five patients underwent antiviral therapy. Serum ferritin, C-reactive protein (CRP), transferrin, albumin, alpha-1 acid glycoprotein (A1AG), and alpha-2 macroglobulin (A2MG) levels were examined at the initial evaluation and at the 4th, 12th, and 48th weeks. HCV RNA levels were examined at the initial evaluation and at the 12th and 48th weeks. Results: Ferritin, transferrin, A1AG, and A2MG levels were significantly higher in the patient group (p<0.05). CRP, ferritin, A1AG, and A2MG levels were significantly increased from baseline to the 4th week (p<0.05). The responders and nonresponders to antiviral therapy had insignificantly but remarkably different levels of CRP, ferritin, transferrin, A1AG, A2MG, and alanine aminotransferase (ALT) both at the initial evaluation and at the 12th week. Conclusions: Variations in ferritin, A1AG, A2MG, albumin, CRP, and transferrin levels are not alternatives to virological and biochemical parameters for predicting an early response to therapy in patients with CHC. However, the investigation of ALT levels and hepatitis C virus RNA in combination with acute-phase reactants may provide supplementary data for evaluating responses to antiviral therapy. (Gut Liver 2013;7:82-88)
 
KEYWORD
Hepatitis C; Acute-phase proteins; Hepatitis C virus RNA
 
Gut and Liver 2013 Jan; 7(1): 82-88
Submit a manuscript
Register
Sign up for article alerts
Log in